fleroxacin has been researched along with ciprofloxacin in 225 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 105 (46.67) | 18.7374 |
1990's | 96 (42.67) | 18.2507 |
2000's | 13 (5.78) | 29.6817 |
2010's | 9 (4.00) | 24.3611 |
2020's | 2 (0.89) | 2.80 |
Authors | Studies |
---|---|
Cohen, MA; Domagala, JM; Mailloux, GB; Roland, GE; Suto, MJ | 1 |
Corraz, AJ; Dax, SL; Dunlap, NK; Georgopapadakou, NH; Keith, DD; Pruess, DL; Rossman, PL; Then, R; Unowsky, J; Wei, CC | 1 |
Bouzard, D; Cesare, PD; Essiz, M; Fung-Tomc, J; Jacquet, JP; Kessler, RE; Kiechel, JR; Ledoussal, B; Remuzon, P | 1 |
Domagala, JM; Heifetz, CL; Hutt, MP; Mich, TF; Nichols, JB; Solomon, M; Worth, DF | 1 |
Domagala, JM; Hanna, LD; Heifetz, CL; Hutt, MP; Mich, TF; Sanchez, JP; Solomon, M | 1 |
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
Asahina, Y; Hosaka, M; Iinuma, F; Ishizaki, T; Iwase, K | 1 |
Jolivette, LJ; Ward, KW | 1 |
Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Alimi, M; Allam, A; Artaud, I; Chevalier, J; Galardon, E; Kascàkovà, S; Maigre, L; Pagès, JM; Réfrégiers, M | 1 |
Allam, A; Alves de Sousa, R; Artaud, I; Dumont, E; Maigre, L; Pagès, JM; Vergalli, J | 1 |
Feistauer, SM; Georgopoulos, A; Georgopoulos, M; Graninger, W; Pfleger, S | 1 |
Hammerschlag, MR; Hyman, CL; Roblin, PM | 1 |
Jones, RN | 1 |
Hancock, RE; Young, M | 1 |
Bartlett, RC; Mazens-Sullivan, MF; McCarter, YS | 1 |
Lubowski, TJ; Nightingale, C; Quintiliani, R; Sweeney, K; Zhi, J | 1 |
Bertasso, A; Georgopapadakou, NH; Pace, J | 1 |
Conejo, MC; García, I; Pascual, A; Perea, EJ | 1 |
Barry, AL; Fuchs, PC | 3 |
Pattyn, SR | 1 |
Amyes, SG; Lewin, CS | 1 |
Cullmann, W | 1 |
Gocke, E | 1 |
Bednarczyk, EM; Gardner, SF; Green, JA; Leisure, G; Miraldi, F; Nelson, AD | 1 |
Auckenthaler, R; Chuard, C; Herrmann, M; Lew, DP; Lucet, JC; Rohner, P; Waldvogel, FA | 1 |
Hoepelman, IM; Keller, N; Overbeek, BP; Raponi, G; Rozenberg-Arska, M; Verhoef, J | 1 |
Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H | 1 |
Herzog, C; Kissling, M; Speck, B | 1 |
Ishikawa, M; Ishikawa, S; Kinoshita, H; Mashita, K; Mizuno, A; Morimoto, K; Sakai, K; Shinagawa, N; Suzuki, T; Yura, J | 1 |
Cho, N; Deguchi, K; Hirabayashi, K; Matsuda, S; Minaguchi, H; Okada, H; Satoh, K; Shimizu, T; Yagami, Y | 1 |
Hamaya, O; Miyamura, R; Ono, K; Saito, I; Suzuki, A; Yokozawa, M | 1 |
Fabian, I; Kletter, Y; Riklis, I; Shalit, I | 1 |
Cullmann, W; Dechène, M; Leying, H | 1 |
Beskid, G; Chan, K; Cleeland, R; Keith, DD; McGarry, CM; Siebelist, J | 1 |
Bouchenaki, N; Huggler, E; Lew, DP; Vaudaux, PE; Waldvogel, FA | 1 |
Hori, S; Kaji, M; Kaneko, S; Kusajima, H; Miyahara, T; Ooie, T; Saito, A; Saito, S; Shiba, K; Shimada, J | 1 |
Hoepelman, AI; Verhoef, J; Wolfhagen, MJ | 1 |
Anderson, R; Joone, G; van Rensburg, CE | 2 |
LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F | 1 |
Jedlicková, Z; Kubín, M; Láznicková, T; Seremek, O | 1 |
Awni, W; Heim-Duthoy, K; Peltier, G | 1 |
Derendorf, H; LeBel, M; Limberg, J | 1 |
Dell, D; Eggers, H; Gora, R; Heizmann, P | 1 |
Dhib, M; Fillastre, JP; Godin, M; Leroy, A; Moulin, B; Singlas, E; Sultan, E; Taburet, AM | 1 |
Devillers, A; Fillastre, JP; Singlas, E; Taburet, AM; Thomare, P; Veyssier, P | 1 |
LeBel, M; Parent, M; St-Laurent, M | 1 |
Altwegg, M; Hohl, P; Lüthy-Hottenstein, J; Zollinger-Iten, J | 1 |
Antonsen, O; Bakøy, OE; Furuheim, KM; Gribbestad, I; Hoogkamer, HF; Jynge, P; Kleinbloesem, CH; Krane, J; Nilsen, OG; Skjetne, T | 1 |
Polak, A | 1 |
Christ, W | 1 |
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H | 1 |
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B | 1 |
Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE | 1 |
Chan, KK; Christenson, JG; Cleeland, R; Dix-Holzknecht, B; Farrish, HH; Patel, IH; Specian, A | 1 |
Felber, AM; Hohl, P | 2 |
Bodey, GP; Ho, DH; LeBlanc, B; Messer, M; Nguyen, H; Rolston, KV | 1 |
Auckenthaler, R; Herrmann, M; Lew, DP; Lucet, JC; Rohner, P; Waldvogel, FA | 1 |
Bacracheva, N; Hayton, WL; Muirhead, G; Portmann, R; Stoeckel, K; Viachki, I; Vlahov, V; Weidekamm, E | 1 |
Brunt, E; Derendorf, H; Limberg, J | 1 |
Albrecht, HA; Beskid, G; Chan, KK; Christenson, JG; Cleeland, R; Deitcher, KH; Georgopapadakou, NH; Keith, DD; Pruess, DL; Sepinwall, J | 1 |
Hori, S; Kawahara, F; Kobayashi, F; Ooie, T; Saito, S; Sakai, O; Shimada, J; Taga, F; Uchida, H | 1 |
Gu, JW; Neu, HC | 1 |
Krcméry, V | 1 |
Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F | 1 |
Grobecker, H; Kees, F; Naber, KG; Schumacher, H | 1 |
Schaefler, S | 1 |
Brandt, R; Frey, FJ; Heizmann, P; Stuck, AE; Weidekamm, E | 1 |
Albrecht, LM; Barriere, SL; Kaatz, GW; Rybak, MJ; Seo, SM | 1 |
Griggs, DJ; Piddock, LJ; Wise, R | 1 |
Hansz, C; Portmann, R; Stiglmayer, R; Weidekamm, E | 1 |
Francoeur, J; Grech-Bélanger, O; Le Bel, M | 1 |
Cameron, DW; D'Costa, L; MacDonald, KS; Ndinya-Achola, JO; Plummer, FA; Ronald, AR | 1 |
Barry, AL; Jones, RN; Thornsberry, C | 1 |
Deforges, L; Duval, J; Leclercq, R; Soussy, CJ | 1 |
Daschner, F; Kropec, A | 2 |
Barzilai, A; Keren, G; Leibovitz, E; Rubinstein, E; Shabtai, M | 1 |
Jehl, F; Koechlin, C; Linger, L; Monteil, H | 1 |
Bowie, WR; Megran, DW; Willetts, V | 1 |
Bowie, WR; Jewesson, PJ; Willetts, V | 1 |
Crokaert, F; Van der Linden, MP; Yourassowsky, E | 1 |
Aubert, G; Denis, M; Dorche, G; Loboguerrero, M; Lucht, F; Puech, C | 1 |
Akalin, HE; Akyön, Y; Diker, S; Gür, D; Hasçelik, G | 1 |
Chapman, JS; Georgopapadakou, NH | 2 |
Bertasso, A; Chapman, JS; Georgopapadakou, NH | 1 |
Bertasso, A; Chan, KK; Chapman, JS; Cleeland, R; Cummings, LM; Dix, BA; Georgopapadakou, NH; Keith, DD | 1 |
Beskid, G; Chan, K; Cleeland, R; Fallat, V; Keith, DD; Lipschitz, ER; McGarry, DH; Unowsky, J | 1 |
Arakawa, S; Fujii, A; Kamidono, S; Maeda, H; Nakata, K | 1 |
Aoyama, H; Hirai, K; Oomori, Y; Suzue, S; Yasue, T; Yokota, T | 1 |
Aoyama, H; Inoue, M; Mitsuhashi, S | 1 |
Buch, A; Falkenberg, FW; Mondorf, AW; Rüdel, C; Steinbacher, G | 1 |
Aoyama, H; Hirai, K; Hosaka, M; Irikura, T; Niwata, Y; Oomori, Y; Suzue, S | 1 |
Brunham, RC; Le Saux, NM; Plummer, FA; Ronald, AR; Slaney, LA | 1 |
Irikura, T; Ishikawa, N; Kusajima, H; Machida, M; Uchida, H | 1 |
Andrews, JM; Manek, N; Wise, R | 1 |
Kawahara, F; Kusajima, H; Ooie, T; Uchida, H | 1 |
Ashby, J; Griggs, DJ; Kirkpatrick, B; Wise, R | 1 |
Fass, RJ; Helsel, VL | 1 |
Dell, D; Stöckel, K; Weidekamm, E | 2 |
Houben, AW; Stobberingh, EE; van Boven, CP | 1 |
Clarke, AM; Zemcov, SJ | 1 |
Easmon, C; Verity, L | 1 |
Easmon, CS; Ison, CA; Woodford, N | 2 |
Kaukoranta-Tolvanen, SS; Renkonen, OV | 1 |
Habiyaremye, I; Vandepitte, J; Verbist, L | 1 |
Gasser, TC; Graversen, PH; Madsen, PO | 1 |
Braveny, I; Machka, K | 1 |
Hohl, P; Kafader, FM; Salfinger, M | 2 |
Verbist, L | 1 |
Hohl, P; von Graevenitz, A; Zollinger-Iten, J | 1 |
Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN; Thornsberry, C | 1 |
Aldridge, KE; Sanders, CV; Schiro, DD | 1 |
Dell, D; Lücker, PW; Partos, C; Portmann, R; Suter, K; Weidekamm, E | 1 |
Hardegger, U; Wüst, J | 1 |
Appelbaum, PC; Spangler, SK; Tamarree, T | 1 |
Boerema, JB; Moesker, HL; Van de Rhee, HJ | 1 |
Claeys, G; Van den Abeele, AM; Verschraegen, G | 1 |
Krausse, R; Ullmann, U | 1 |
Ernst, F; van der Auwera, P | 1 |
Andrews, JM; Ashby, JP; Matthews, RS; Wise, R | 1 |
Butler, T; Farhi, D; Jacobs, MR | 1 |
Abeck, D; Alexander, F; Ballard, RC; Johnson, AP; Korting, HC | 1 |
Awni, WM; Heim-Duthoy, KL; Maloney, JA | 1 |
Benonisen, E; Digranes, A; Salveson, A; Zahm, F | 1 |
Cullmann, W; Dechène, M; Stieglitz, M | 1 |
De Lepeleire, I; De Schepper, PJ; Tjandra-Maga, TB; Van Hecken, A; Verbesselt, R | 1 |
Andrews, JM; Ashby, JP; Honeybourne, D; Wise, R | 1 |
Bergeron, MG; LeBel, M; Panneton, AC | 1 |
Burdon, DW; Keighley, MR; Tudor, RG; Yoshioka, K; Youngs, DJ | 1 |
Keighley, MR; Tudor, RG; Yoshioka, K; Youngs, DJ | 1 |
Ritzerfeld, W | 1 |
Fabrig, J; Hof, H | 1 |
Niki, Y; Soejima, R; Tasaka, Y; Umeki, S; Watanabe, M | 1 |
Itaya, T; Kanamaru, M; Kawahara, F; Mizuno, A; Nakashima, M; Ooie, T; Saito, S; Takiguchi, A; Uchida, H; Uematsu, T | 1 |
Dell, D; Partos, C; Portmann, R; Weidekamm, E | 1 |
Metz, R; Muth, P; Naber, K; Seelmann, R; Sorgel, F | 2 |
Bremner, DA; Dickie, AS; Singh, KP | 1 |
Ashby, JP; Griggs, DJ; Kirkpatrick, B; Wise, R | 1 |
Baba, S; Maruo, T; Mori, Y | 1 |
Knothe, H; Sammann, A; Schäfer, V; Seczendi, M; Shah, PM | 1 |
Kaspersen, P; Korsager, B; Mamsen, A; Møller, BR; Quitzau, K | 1 |
Adamis, G; Gargalianos, P; Kosmidis, J; Makris, D; Petropoulou, D | 1 |
Ellmén, J; Lassus, A; Renkonen, OV | 1 |
Ackenheil-Köppe, HR; Meier-Ewert, H; Pust, RA; Weidner, W | 1 |
Breyer, S; Georgopoulos, A; Georgopoulos, M; Graninger, W; Mailer, H | 1 |
Braunsteiner, A; Herzog, C; Hohl, P; Paganoni, R | 1 |
Dubois, J; Fontaine, V | 1 |
Pohlod, DJ; Saravolatz, LD; Somerville, MM | 2 |
Crokaert, F; Glupczynski, Y; Lismont, MJ; Van der Linden, MP; Yourassowsky, E | 1 |
Meier-Ewert, H; Steele-Mortimer, O | 1 |
Bauernfeind, A; Eberlein, E; Hörl, G | 1 |
Fernandes, PB; Swanson, RN | 1 |
Bodey, GP; Ho, DH; LeBlanc, B; Rolston, K | 1 |
Nagayama, A; Nakao, T; Taen, H | 1 |
Kafetzis, DA; Legakis, NJ | 1 |
Houben, A; Stobberingh, E; Van Boven, C | 1 |
Eichmann, A; Eugster, H | 1 |
Johnson, DM; Jones, RN | 1 |
Carbon, C; Dautrey, S; Farinoti, R; Ramon, J; Rubinstein, E; St Julien, L | 1 |
Beskid, G; Prosser, BL | 2 |
Cormican, MG; Jones, RN; Marshall, SA | 1 |
Arman, D; Tural, D; Willke, A | 1 |
Goldwasser, R; Keren, G; Keysary, A; Rubinstein, E | 1 |
Jones, RN; Sanchez, ML | 1 |
Haen, E; Kurz, H; Przybilla, B; Tiefenbacher, EM | 1 |
Griffiths, NM; Hirst, BH; Simmons, NL | 1 |
Coll, R; Esteve, M; Garcia, J; Gargallo-Viola, D; Guinea, J; Pares, M; Robert, M; Roser, R; Tudela, E; Xicota, MA | 1 |
Hendrickx, AG; Hummler, H; Richter, WF | 1 |
Iravani, A | 1 |
Coll, R; Mirelis, B; Miró, E; Navarro, F; Prats, G; Xicota, MA | 1 |
Hoogkamer, JF; Kleinbloesem, CH | 1 |
Esguerra, EM; Fu, Q; Nicolau, DP; Nightingale, CH; Quintiliani, R; Tessier, PR; Xuan, DW | 1 |
Cheung, MM; Ho, NK; Kam, KM; Wong, PW | 1 |
Demeure, MP; Edmiston, CE; Frantzides, CT; Schulte, WJ; Suarez, EC; Walker, AP; Wilson, SD | 1 |
Marklein, G | 1 |
Aoun, M; Crokaert, F; Duchateau, V; Grenier, P; Klastersky, J; Vandermies, A | 1 |
Albertini, S; Chételat, AA; Gocke, E | 1 |
Gmünder, H; Keck, W; Kuratli, K | 1 |
Klecak, G; Urbach, F; Urwyler, H | 1 |
Forbes, PD; Mäkinen, M; Stenbäck, F | 1 |
Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K | 1 |
Beil, WJ; Georgopoulos, A; Graninger, W; Griesmacher, A; Hlousek, M; Robibaro, B; Schaumann, R; Vorbach, H; Weigel, G | 1 |
Bischoff, W; Frankenschmidt, A; Kullmann, K; Naber, KG | 1 |
Muszynski, MJ; Rajyaguru, JM | 1 |
Ebisuno, S; Inagaki, T; Kohjimoto, Y; Ohkawa, T | 1 |
Förster, C; Günther, T; Lozo, E; Merker, HJ; Schwabe, R; Stahlmann, R; Vormann, J; Zippel, U | 1 |
Kawada, A; Kimura, M | 1 |
Armbruster, C; Georgopoulos, A; Graninger, W; Griesmacher, A; Hlousek, M; Reiter, M; Robibaro, B; Vorbach, H; Weigel, G | 1 |
Baumann-Wilschke, I; Förster, C; Rücker, M; Shakibaei, M; Stahlmann, R; Vormann, J | 1 |
Gabutti, L; Marti, HP; Stoller, R | 1 |
Ansorg, R; Fabry, W; Schmid, EN | 1 |
Pons, G; Rey, E; Tréluyer, JM | 1 |
Armitage, HT; Kerr, KG; McWhinney, PH | 1 |
Gomi, H; Hatanaka, K; Kawada, A; Matsuo, I | 1 |
Begg, EJ; Buttimore, RC; Graham, GG; Neill, AM; Robson, RA; Saunders, DA; Town, GI | 1 |
Chukwuani, CM; Coker, HA; Ifudu, ND; Oduola, AM; Sowunmi, A | 1 |
Bouquet, S; Couet, W; de Boer, AG; de Lange, EC; Delon, A; Marchand, S; van den Berg, D; van der Sandt, IC | 1 |
Fukuda, H; Kawamura, Y | 1 |
Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
Kim, MK; Nicolau, D; Nightingale, C | 1 |
Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
Cvijovic, M; Di Marco, V; Djurdjevic, P; Stankov, MJ; Traldi, P | 1 |
Fang, G; Gao, J; Gao, X; Li, J; Liu, H; Liu, X; Lu, X; Tang, Y; Wang, J | 1 |
Conraux, L; Dumont, E; Mourez, M; Pagès, JM; Pajovic, J; Réfrégiers, M; Taillier, C; Vassort, A; Vergalli, J | 1 |
Li, K; Liu, Y; Liu, Z; Yu, W; Zhang, H | 1 |
Gao, M; Li, H; Li, W; Pan, X; Shan, L; Tian, H; Wang, J | 1 |
2 review(s) available for fleroxacin and ciprofloxacin
Article | Year |
---|---|
Pharmacokinetics of quinolones in renal insufficiency.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Glomerular Filtration Rate; Half-Life; Humans; Kidney Failure, Chronic; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones | 1990 |
Drug disposition in cystic fibrosis.
Topics: Absorption; Anti-Infective Agents; Ciprofloxacin; Cloxacillin; Cyclosporine; Cystic Fibrosis; Fleroxacin; Humans; Theophylline; Tissue Distribution | 1998 |
19 trial(s) available for fleroxacin and ciprofloxacin
Article | Year |
---|---|
Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
Topics: Administration, Oral; Adult; Blister; Body Fluids; Ciprofloxacin; Female; Fleroxacin; Humans; Male; Middle Aged; Random Allocation | 1992 |
An assessment of cerebral blood flow and metabolism after fleroxacin therapy.
Topics: Adult; Animals; Anti-Infective Agents; Cerebral Cortex; Cerebrovascular Circulation; Ciprofloxacin; Evaluation Studies as Topic; Fleroxacin; Glucose; Humans; Male; Oxygen; Tomography, Emission-Computed | 1991 |
[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Ciprofloxacin; Female; Fleroxacin; Humans; Male; Middle Aged; Time Factors; Urinary Tract Infections | 1991 |
Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fleroxacin; Humans; Klebsiella; Male; Middle Aged; Pseudomonas aeruginosa; Randomized Controlled Trials as Topic; Urinary Tract Infections | 1990 |
Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Chancroid; Ciprofloxacin; Evaluation Studies as Topic; Fleroxacin; Haemophilus ducreyi; HIV; Humans; Kenya; Male; Middle Aged | 1989 |
Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; Doxycycline; Female; Fleroxacin; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Urethritis | 1989 |
Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Drug Interactions; Female; Fleroxacin; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Middle Aged; Patient Compliance; Photosensitivity Disorders; Randomized Controlled Trials as Topic; Sleep Wake Disorders | 1989 |
Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Topics: Administration, Oral; Biological Availability; Ciprofloxacin; Drug Interactions; Fleroxacin; Humans; Infusions, Intravenous; Male; Probenecid | 1987 |
Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
Topics: Administration, Oral; Adult; Ciprofloxacin; Fleroxacin; Humans; Male; Pefloxacin; Random Allocation | 1988 |
Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Female; Fleroxacin; Humans; Middle Aged; Proteus mirabilis; Random Allocation; Staphylococcus aureus; Urinary Tract Infections | 1988 |
Fleroxacin versus standard therapy in gonococcal urethritis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Follow-Up Studies; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Urethritis | 1988 |
Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Female; Fleroxacin; Humans; Middle Aged; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 1993 |
The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fleroxacin; Food-Drug Interactions; Humans; Male; Milk | 1995 |
The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine.
Topics: Adult; Anti-Infective Agents; Caffeine; Central Nervous System Stimulants; Ciprofloxacin; Cross-Over Studies; Female; Fleroxacin; Humans; Male; Single-Blind Method | 1995 |
Penetration of ciprofloxacin and fleroxacin into biliary tract.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bile; Biliary Tract; Cholecystectomy; Ciprofloxacin; Female; Fleroxacin; Gallbladder; Humans; Male; Middle Aged | 1996 |
Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Double-Blind Method; Female; Fleroxacin; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Respiratory Tract Infections | 1996 |
Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Drug Administration Schedule; Female; Fleroxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Urinary Tract Infections | 1997 |
The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bronchiectasis; Bronchitis; Chronic Disease; Ciprofloxacin; Female; Fleroxacin; Humans; Male; Middle Aged; Models, Biological; Sputum; Time Factors | 2000 |
Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Topics: Administration, Oral; Adult; Area Under Curve; Body Weight; Caffeine; Ciprofloxacin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Female; Fleroxacin; Humans; Male; Sex Factors | 2003 |
204 other study(ies) available for fleroxacin and ciprofloxacin
Article | Year |
---|---|
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
Topics: Animals; Anti-Infective Agents; Cricetinae; Cricetulus; Fluoroquinolones; Microbial Sensitivity Tests; Structure-Activity Relationship | 1992 |
Dual-action penems and carbapenems.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Microbial Sensitivity Tests | 1992 |
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Dogs; Indicators and Reagents; Mice; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Structure-Activity Relationship | 1991 |
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Carboxylic Acids; Chemical Phenomena; Chemistry; Mice; Microbial Sensitivity Tests; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1988 |
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
Topics: Anti-Bacterial Agents; Bacteria; DNA, Bacterial; DNA, Superhelical; Escherichia coli; Microbial Sensitivity Tests; Naphthyridines; Plasmids; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1986 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
Topics: Anti-Bacterial Agents; Carboxylic Acids; Fleroxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Models, Molecular; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship | 2005 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging.
Topics: | 2013 |
New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Cell Membrane Permeability; Cephalosporins; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacter aerogenes; Escherichia coli; Framycetin; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Organometallic Compounds | 2017 |
Antibacterial activity of sparfloxacin against experimental renal infections in mice.
Topics: Abscess; Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Fleroxacin; Fluoroquinolones; Half-Life; Kidney Diseases; Methicillin Resistance; Mice; Quinolones; Staphylococcal Infections | 1992 |
In vitro activities of five quinolones against Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydophila pneumoniae; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1992 |
In vitro evaluation of E-4695, a new fluoro-naphthyridine.
Topics: Anti-Bacterial Agents; Azetidines; Bacteria; Ciprofloxacin; Drug Evaluation, Preclinical; Enoxacin; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Quinolones | 1992 |
Fluoroquinolone supersusceptibility mediated by outer membrane protein OprH overexpression in Pseudomonas aeruginosa: evidence for involvement of a nonporin pathway.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Cell Membrane; Chloramphenicol; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Gene Expression; Norfloxacin; Porins; Pseudomonas aeruginosa | 1992 |
The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1992 |
Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carrier Proteins; Cefotaxime; Cell Membrane Permeability; Cephalosporins; Ciprofloxacin; Coliphages; DNA Replication; DNA, Bacterial; Drug Resistance, Microbial; Escherichia coli; Fleroxacin; Fluoroquinolones; Gene Expression Regulation, Bacterial; Hexosyltransferases; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Mutation; Penicillin-Binding Proteins; Peptidyl Transferases; Porins | 1991 |
Fluorometric and high-performance liquid chromatographic measurement of quinolone uptake by human neutrophils.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Fluorescence; Fluoroquinolones; Humans; Neutrophils; Norfloxacin; Ofloxacin; Quinolones | 1991 |
Cross-resistance and cross-susceptibility between fluoroquinolone agents.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Predictive Value of Tests; Quinolones | 1991 |
Anti-Mycobacterium leprae activity of several quinolones studied in the mouse.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Leprosy; Mice; Mycobacterium leprae; Quinolones | 1991 |
Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
Topics: Anti-Infective Agents; Bacterial Proteins; Chloramphenicol; Ciprofloxacin; Escherichia coli; Fleroxacin; Pefloxacin; Rifampin; RNA, Bacterial | 1990 |
Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates.
Topics: Bacterial Outer Membrane Proteins; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Humans; Pseudomonas aeruginosa; Xanthomonas | 1991 |
Mechanism of quinolone mutagenicity in bacteria.
Topics: Anti-Infective Agents; Blotting, Southern; Ciprofloxacin; DNA Topoisomerases, Type II; Enrofloxacin; Escherichia coli; Fleroxacin; Fluoroquinolones; Genes, Bacterial; Mutation; Novobiocin; Ofloxacin; Oxolinic Acid; Quinolones; Salmonella | 1991 |
Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Diffusion Chambers, Culture; Disease Models, Animal; Drug Resistance, Microbial; Fleroxacin; Foreign Bodies; Gentamicins; Kinetics; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Rats; Rats, Inbred Strains; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1991 |
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Topics: Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines | 1991 |
Effect of sub-minimal inhibitory concentrations of ciprofloxacin and fleroxacin on the bacterial capsular antigen and opsonophagocytosis by human polymorphonuclear leukocytes.
Topics: Agglutination Tests; Anti-Infective Agents; Antigens, Bacterial; Cell Wall; Ciprofloxacin; Escherichia coli; Fleroxacin; Humans; Klebsiella; Neutrophils; Opsonin Proteins; Phagocytosis; Polysaccharides, Bacterial; Staphylococcus aureus | 1991 |
Effect of fleroxacin and ciprofloxacin on the formation of human mature colonies of healthy donor versus transplanted hemopoietic progenitor cells.
Topics: Bone Marrow Cells; Bone Marrow Transplantation; Ciprofloxacin; Colony-Forming Units Assay; Fleroxacin; Hematopoietic Stem Cells; Humans | 1991 |
[Clinical study on fleroxacin in surgical infections].
Topics: Abscess; Administration, Oral; Adolescent; Adult; Aged; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Female; Fleroxacin; Humans; Male; Mastitis; Middle Aged; Rectal Diseases; Surgical Wound Infection | 1991 |
[Clinical evaluation of fleroxacin in gynecological infections].
Topics: Administration, Oral; Adolescent; Adult; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluation; Drug Resistance, Microbial; Female; Fleroxacin; Genital Diseases, Female; Humans; Middle Aged | 1991 |
[Bacteriological and clinical studies on fleroxacin in male gonococcal urethritis].
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Drug Evaluation; Drug Resistance, Microbial; Fleroxacin; Gonorrhea; Humans; Male; Neisseria gonorrhoeae; Urethritis | 1991 |
Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin.
Topics: Animals; Antibodies; Bone Marrow; Bone Marrow Cells; Ceftazidime; Cell Division; Cells, Cultured; Ciprofloxacin; Colony-Stimulating Factors; Fleroxacin; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Interleukin-3; Male; Mice; Mice, Inbred BALB C; Pokeweed Mitogens; Spleen | 1991 |
Role of the outer membrane for quinolone resistance in enterobacteria.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Escherichia coli; Fleroxacin; Lipopolysaccharides; Nalidixic Acid; Ofloxacin; Serratia marcescens; Species Specificity | 1990 |
In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Drug Evaluation, Preclinical; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Klebsiella pneumoniae; Meningitis; Mice; Neutropenia; Penicillin Resistance; Pneumonia; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes; Time Factors | 1990 |
Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Fleroxacin; Foreign Bodies; Guinea Pigs; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1990 |
Renal handling of fleroxacin in rabbits, dogs, and humans.
Topics: Adult; Animals; Blood Proteins; Ciprofloxacin; Creatinine; Dogs; Fleroxacin; Glomerular Filtration Rate; Humans; Kidney; Kinetics; Male; Probenecid; Protein Binding; Rabbits; Species Specificity | 1990 |
Interactions of the oxygen-dependent antimicrobial system of the human neutrophil with difloxacin, ciprofloxacin, pefloxacin and fleroxacin in the intraphagocytic eradication of Staphylococcus aureus.
Topics: Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Granulomatous Disease, Chronic; Humans; Neutrophils; Pefloxacin; Phagocytosis; Staphylococcus aureus | 1990 |
Altered disposition of fleroxacin in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Administration Schedule; Extracellular Space; Female; Fleroxacin; Humans; Male; Reference Values | 1990 |
The antimicrobial activity of Fleroxacin RO 23-6240, a third generation fluoroquinolone derivative, tested in vitro.
Topics: Bacteria; Ciprofloxacin; Fleroxacin; Microbial Sensitivity Tests; Mycobacterium | 1990 |
Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Topics: Adult; Ciprofloxacin; Fleroxacin; Half-Life; Humans; Male; Skin Diseases, Infectious | 1990 |
Evaluation of free tissue concentrations of fleroxacin after oral administration.
Topics: Administration, Oral; Adult; Blister; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans; Male | 1990 |
Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans; Spectrometry, Fluorescence | 1990 |
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fleroxacin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 1990 |
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Female; Fleroxacin; Humans; Male | 1990 |
Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
Topics: Adult; Aged; Aging; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Fleroxacin; Humans; Male; Theophylline | 1990 |
In vitro activities of fleroxacin, cefetamet, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against rare members of the family Enterobacteriaceae primarily of human (clinical) origin.
Topics: Amoxicillin; Anti-Bacterial Agents; Ceftizoxime; Ceftriaxone; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Enterobacteriaceae; Enterobacteriaceae Infections; Fleroxacin; Humans; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination | 1990 |
In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Fluorine; Humans; Liver; Magnetic Resonance Spectroscopy; Muscles | 1990 |
In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone.
Topics: Animals; Anti-Infective Agents; Antifungal Agents; Candida albicans; Candidiasis; Ciprofloxacin; Drug Interactions; Drug Therapy, Combination; Fleroxacin; Male; Mice | 1990 |
Central nervous system toxicity of quinolones: human and animal findings.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Central Nervous System; Ciprofloxacin; Dogs; Drug Interactions; Fleroxacin; Fluoroquinolones; gamma-Aminobutyric Acid; Humans; Injections, Intraventricular; Narcotic Antagonists; Pefloxacin; Quinolizines; Seizures; Theophylline | 1990 |
Quinolone pharmacokinetics and metabolism.
Topics: Administration, Oral; Anti-Infective Agents; Biological Availability; Biotransformation; Ciprofloxacin; Enoxacin; Fleroxacin; Half-Life; Humans; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Pefloxacin | 1990 |
Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Fleroxacin; Humans; Microbial Sensitivity Tests; Sputum | 1990 |
Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Chromatography, High Pressure Liquid; Ciprofloxacin; Dogs; Fleroxacin; Fluoroquinolones; Humans; Injections, Intravenous; Mice; Papio; Rats; Species Specificity | 1990 |
In vitro activity of fleroxacin against aerobic gram-positive bacteria including Corynebacterium jeikeium.
Topics: Bacteria, Aerobic; Ciprofloxacin; Corynebacterium; Fleroxacin; Gram-Positive Bacteria; Microbial Sensitivity Tests; Norfloxacin; Streptococcus pyogenes | 1990 |
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms | 1990 |
Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Fleroxacin; Foreign-Body Reaction; Male; Methicillin Resistance; Microbial Sensitivity Tests; Rats; Rats, Inbred Strains; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1990 |
Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Bile; Biotransformation; Cholecystectomy; Ciprofloxacin; Female; Fleroxacin; Half-Life; Humans; Male | 1990 |
High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic.
Topics: Anti-Infective Agents; Blood Proteins; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Stability; Erythrocytes; Fleroxacin; Humans; Protein Binding | 1990 |
Cephalosporin 3'-quinolone esters with a dual mode of action.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Cephalosporins; Chemical Phenomena; Chemistry; Ciprofloxacin; Enterobacter; Escherichia coli Infections; Fleroxacin; Fluoroquinolones; Hydrolysis; Mice; Molecular Structure; Pneumococcal Infections; Prodrugs; Quinolones; Rats; Staphylococcus aureus; Structure-Activity Relationship | 1990 |
Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals.
Topics: Animals; Brain; Central Nervous System; Ciprofloxacin; Cisterna Magna; Dogs; Fleroxacin; In Vitro Techniques; Indicators and Reagents; Infusions, Intravenous; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Rats; Rats, Inbred Strains; Receptors, GABA-A; Seizures | 1990 |
In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Cefotaxime; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests | 1990 |
[Dual cephalosporins--a return of fixed combinations of antibiotics?].
Topics: Anti-Infective Agents; Bacteria; Cefotaxime; Ciprofloxacin; Drug Combinations; Fleroxacin; Fluoroquinolones | 1990 |
In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Body Fluids; Ciprofloxacin; Fleroxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prostatic Hyperplasia; Seminal Vesicles; Urinary Tract Infections | 1988 |
Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
Topics: Administration, Oral; Aged; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans; Injections, Intravenous; Iothalamic Acid; Male; Middle Aged; Prostate; Prostatic Hyperplasia | 1988 |
Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Humans; Methicillin; Penicillin Resistance; Staphylococcus aureus | 1989 |
Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fleroxacin; Glomerular Filtration Rate; Humans; Injections, Intravenous; Kidney Diseases; Male; Middle Aged; Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Protein Binding | 1989 |
Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Topics: Animals; Ciprofloxacin; Drug Resistance, Microbial; Endocarditis, Bacterial; Fleroxacin; Male; Methicillin; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 1989 |
The killing action of fleroxacin upon Bacteroides fragilis.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; Cell Cycle; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Microbial Sensitivity Tests | 1989 |
Fleroxacin concentrations in myometrium, ovary and fallopian tube.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Fallopian Tubes; Female; Fleroxacin; Humans; Middle Aged; Myometrium; Ovary; Time Factors | 1989 |
The effect of fleroxacin on hepatic drug metabolism in the rat.
Topics: Animals; Anti-Infective Agents; Antipyrine; Ciprofloxacin; Cytochrome P-450 Enzyme System; Fleroxacin; In Vitro Techniques; Liver; Male; Microsomes, Liver; Pharmaceutical Preparations; Rats; Rats, Inbred Strains | 1989 |
Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.
Topics: Anti-Infective Agents; Bacteria; Cefotaxime; Ciprofloxacin; Drug Combinations; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 1989 |
An in vitro investigation of the intraphagocytic bioactivity of difloxacin, ciprofloxacin, pefloxacin and fleroxacin.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Phagocytes | 1989 |
[In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fleroxacin; Microbial Sensitivity Tests; Nalidixic Acid; Pefloxacin | 1989 |
In vitro activity of fleroxacin and 14 other antimicrobials against slime- and non-slime-producing Staphylococcus epidermidis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Fleroxacin; Staphylococcus epidermidis | 1989 |
In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Enoxacin; Fleroxacin; Humans; Microbial Sensitivity Tests; Ofloxacin; Tobramycin | 1989 |
The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.
Topics: Abscess; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Enterobacteriaceae Infections; Female; Fleroxacin; Half-Life; Pefloxacin; Rats; Serratia marcescens | 1989 |
High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids.
Topics: Anti-Infective Agents; Bile; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Humans; Molecular Structure; Naphthyridines; Quinolones; Spectrometry, Fluorescence | 1989 |
Correlation between growth curves and killing curves of Escherichia coli in the presence of fleroxacin and ampicillin.
Topics: Ampicillin; Ampicillin Resistance; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Culture Media; Drug Resistance, Microbial; Escherichia coli; Fleroxacin; Nephelometry and Turbidimetry; Species Specificity; Time Factors | 1989 |
[Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enoxacin; Escherichia coli; Fleroxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Pefloxacin; Pseudomonas aeruginosa; Serratia marcescens | 1989 |
[In vitro susceptibility of Campylobacter jejuni and Campylobacter coli to quinolone antibiotics].
Topics: Anti-Infective Agents; Campylobacter; Campylobacter jejuni; Ciprofloxacin; Feces; Fleroxacin; Humans; Microbial Sensitivity Tests; Ofloxacin; Pefloxacin | 1989 |
Fluorometric assay for fleroxacin uptake by bacterial cells.
Topics: Ciprofloxacin; Escherichia coli; Fleroxacin; Quinolones; Spectrometry, Fluorescence | 1989 |
Fleroxacin resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Fleroxacin; Microbial Sensitivity Tests | 1989 |
Mode of action of the dual-action cephalosporin Ro 23-9424.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carrier Proteins; Cefotaxime; Cephalosporins; Ciprofloxacin; DNA Replication; DNA, Bacterial; Enterobacter; Escherichia coli; Fleroxacin; Fluoroquinolones; Hexosyltransferases; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Staphylococcus aureus | 1989 |
In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.
Topics: Anti-Bacterial Agents; Bacteria; Cefotaxime; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Pseudomonas | 1989 |
In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
Topics: Anti-Infective Agents; Chlamydia; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Naphthyridines; Quinolones | 1988 |
Effects of fleroxacin on HeLa cell functions and topoisomerase II.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; Fleroxacin; HeLa Cells; Humans | 1988 |
In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fleroxacin; Microbial Sensitivity Tests | 1988 |
Renal tolerance of fleroxacin in healthy volunteers.
Topics: Adult; Aminopeptidases; Anti-Infective Agents; Antibodies, Monoclonal; Antigens; CD13 Antigens; Ciprofloxacin; Creatinine; Fleroxacin; Humans; Kidney; Male | 1988 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Male; Mice; Mice, Inbred ICR; Norfloxacin; Ofloxacin; Oxazines; Pneumonia; Quinolines; Urinary Tract Infections | 1986 |
In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
Topics: Cefmenoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Erythromycin; Fleroxacin; Haemophilus ducreyi; Humans; Neisseria gonorrhoeae; Penicillins; Spectinomycin; Tetracycline | 1987 |
Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys.
Topics: Animals; Anti-Infective Agents; Bile; Chromatography, High Pressure Liquid; Ciprofloxacin; Dogs; Female; Fleroxacin; Half-Life; Kinetics; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Rabbits; Rats; Rats, Inbred Strains; Tissue Distribution | 1986 |
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.
Topics: Anti-Bacterial Agents; Bacteria; Bacteroides; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Humans; Lactams; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae | 1986 |
High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Dogs; Fleroxacin; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Rabbits; Rats; Rats, Inbred Strains; Species Specificity | 1986 |
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Blister; Ciprofloxacin; Exudates and Transudates; Fleroxacin; Humans; Kinetics; Male | 1987 |
In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Fleroxacin; Humans; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1987 |
A new trifluorinated quinolone: Ro 23-6240 (AM 833).
Topics: Adult; Biological Availability; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Half-Life; Humans; Kidney; Kinetics; Metabolic Clearance Rate | 1987 |
In vitro evaluation of Ro 23-6240, a new fluorinated 4-quinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Enterobacteriaceae; Fleroxacin; Hydrogen-Ion Concentration; Lactams; Microbial Sensitivity Tests; Mutation; Pseudomonas; Regression Analysis | 1987 |
In vitro activity of the new 4-quinolone compound Ro 23-6240.
Topics: Anti-Bacterial Agents; Bacteria; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Microbial; Enterobacteriaceae; Fleroxacin; Gentamicins; Haemophilus influenzae; Microbial Sensitivity Tests; Nalidixic Acid; Norfloxacin; Pefloxacin; Pseudomonas aeruginosa; Staphylococcus aureus | 1987 |
Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Fleroxacin; Humans; Macrophages; Mice; Mycobacterium; Nontuberculous Mycobacteria; Rifampin | 1987 |
The activity of the 4 quinolone Ro 23 6240 and the cephalosporins Ro 15 8074 and Ro 19 5247 against penicillin sensitive and resistant gonococci.
Topics: Anti-Bacterial Agents; Cefmenoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Fleroxacin; Neisseria gonorrhoeae; Penicillin Resistance | 1987 |
In vitro susceptibility of Neisseria gonorrhoeae to RO 23-6240 and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fleroxacin; Humans; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 1987 |
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Topics: Anti-Bacterial Agents; Campylobacter fetus; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1987 |
Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dogs; Escherichia coli; Extracellular Space; Fleroxacin; Humans; Hydrogen-Ion Concentration; Male; Microbial Sensitivity Tests; Prostate; Tissue Distribution | 1987 |
Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Enterobacteriaceae; Enterococcus faecalis; Fleroxacin; Norfloxacin; Ofloxacin; Oxazines; Pseudomonas aeruginosa; Staphylococcus | 1987 |
In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.
Topics: Amikacin; Anti-Bacterial Agents; Cefmenoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Drug Combinations; Fleroxacin; Mycobacterium; Nontuberculous Mycobacteria; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1987 |
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines | 1987 |
Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fleroxacin; Gram-Negative Bacteria; Legionella; Microbial Sensitivity Tests | 1987 |
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Fleroxacin; Humans; Microbial Sensitivity Tests; Species Specificity | 1987 |
RO23-6240, a new orally absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Imipenem; Microbial Sensitivity Tests; Thienamycins | 1987 |
Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Ceftizoxime; Cephalosporins; Ciprofloxacin; Fleroxacin; Humans | 1987 |
Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
Topics: Anti-Bacterial Agents; Aztreonam; Ciprofloxacin; Fleroxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Ofloxacin; Oxazines | 1988 |
Fleroxacin (Ro 23-6240) in the treatment of gonorrhoea.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Gonorrhea; Humans; Male | 1988 |
Routes of quinolone permeation in Escherichia coli.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Membrane Permeability; Ciprofloxacin; Escherichia coli; Fleroxacin; Magnesium; Magnesium Chloride; Quinolines; Spectrometry, Fluorescence | 1988 |
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
Topics: Amikacin; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Cefaclor; Ceftazidime; Cefuroxime; Ciprofloxacin; Clavulanic Acids; Corynebacterium; Drug Combinations; Drug Resistance, Microbial; Fleroxacin; Norfloxacin; Pefloxacin; Piperacillin; Staphylococcus; Vancomycin | 1988 |
Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Fleroxacin; Humans; Leucomycins; Mycoplasma; Ofloxacin; Oxazines; Ureaplasma | 1988 |
In-vitro activity of fleroxacin (Ro 23-6240), a new fluoro-quinolone, and other agents, against Mycobacterium spp.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Humans; Mycobacterium | 1988 |
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacteria; Blood Proteins; Cefuroxime; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Ofloxacin; Oxazines; Protein Binding; Pseudomonas aeruginosa; Quinolines; Quinolones; Staphylococcus; Streptococcus; Trimethoprim | 1988 |
Treatment of experimental Salmonella typhimurium infection in mice with fleroxacin.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Female; Fleroxacin; Mice; Salmonella Infections, Animal; Salmonella typhimurium | 1988 |
In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fleroxacin; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Penicillin Resistance; Rifamycins; Tetracycline Resistance | 1988 |
Liquid-chromatographic determination of fleroxacin in serum and urine.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans | 1988 |
In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Culture Media; Fleroxacin; Hydrogen-Ion Concentration; Ofloxacin | 1988 |
[Comparative antibacterial activity of fleroxacin: selection frequencies and outer membrane proteins of resistant mutants].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Outer Membrane Proteins; Ciprofloxacin; Drug Combinations; Drug Resistance, Microbial; Escherichia coli; Fleroxacin; Humans; Mutation; Ofloxacin; Serratia marcescens; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
The penetration of fleroxacin into bronchial mucosa.
Topics: Biopsy; Bronchi; Ciprofloxacin; Fleroxacin; Humans; Mucous Membrane | 1988 |
Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
Topics: Administration, Oral; Adult; Body Fluids; Chromatography, High Pressure Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Fleroxacin; Humans; Male; Tissue Distribution | 1988 |
A comparison of the penetration of two quinolones into intra-abdominal abscess.
Topics: Abdomen; Abscess; Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Preclinical; Fleroxacin; Injections, Intravenous; Male; Permeability; Rats; Rats, Inbred Strains; Time Factors; Tissue Distribution | 1988 |
Fleroxacin, a long acting fluoroquinolone with broad spectrum activity. International Congress of Chemotherapy. Istanbul, Turkey, 19-24 July 1987. Proceedings.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Humans | 1988 |
The penetration of fleroxacin into intra-abdominal abscesses.
Topics: Abdomen; Abscess; Animals; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Male; Rats; Rats, Inbred Strains | 1988 |
Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Fleroxacin; Half-Life; Klebsiella; Ofloxacin; Pseudomonas aeruginosa; Pyelonephritis; Rats; Rats, Inbred Strains | 1988 |
Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Fleroxacin; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Norfloxacin; Salmonella Infections, Animal; Salmonella typhimurium | 1988 |
Therapeutic effect of fleroxacin against experimental pneumonia in mice.
Topics: Animals; Anti-Infective Agents; Cefaclor; Ciprofloxacin; Fleroxacin; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Pipemidic Acid | 1988 |
Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Drug Tolerance; Fleroxacin; Half-Life; Humans; Male; Protein Binding; Saliva | 1988 |
Single and multiple dose pharmacokinetics of fleroxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Fleroxacin; Half-Life; Humans; Male | 1988 |
Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Body Fluids; Ciprofloxacin; Fleroxacin; Half-Life; Humans; Kidney; Male; Saliva; Sweat; Tears | 1988 |
Metabolism of fleroxacin in man.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Half-Life; Humans; Kidney; Male | 1988 |
In-vitro activity of fleroxacin compared with three other quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin | 1988 |
The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans; Male | 1988 |
Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil.
Topics: Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Humans; Maxillary Sinus; Mucous Membrane; Palatine Tonsil; Premedication; Tonsillectomy | 1988 |
Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Feces; Fleroxacin; Humans; Male | 1988 |
Fleroxacin in the treatment of uncomplicated acute cystitis in women.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Cystitis; Female; Fleroxacin; Follow-Up Studies; Humans | 1988 |
Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis.
Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; Drug Tolerance; Female; Fleroxacin; Humans; Male; Urethritis | 1988 |
In-vitro activity of fleroxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Microbial Sensitivity Tests | 1988 |
Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Fleroxacin; Microbial Sensitivity Tests; Norfloxacin | 1988 |
In-vitro activity of fleroxacin against urinary tract and genital tract pathogens.
Topics: Ampicillin; Anti-Infective Agents; Bacteria; Ciprofloxacin; Female; Fleroxacin; Genital Diseases, Female; Genital Diseases, Male; Male; Nalidixic Acid; Penicillins; Tetracyclines; Trimethoprim; Urinary Tract Infections | 1988 |
In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Fleroxacin; Microbial Sensitivity Tests; Staphylococcus aureus; Staphylococcus epidermidis | 1988 |
Rate of bactericidal activity for Branhamella catarrhalis of fleroxacin compared with that of amoxycillin-clavulanic acid.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acids; Culture Media; Drug Therapy, Combination; Fleroxacin; Microbial Sensitivity Tests; Moraxella catarrhalis | 1988 |
Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
Topics: Anti-Infective Agents; Cefoxitin; Ciprofloxacin; Erythromycin; Fleroxacin; Humans; Legionella; Macrophages; Microbial Sensitivity Tests; Rifampin | 1988 |
Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Stability; Fleroxacin; Microbial Sensitivity Tests; Mycobacterium | 1988 |
In-vitro activity of fleroxacin against Chlamydia trachomatis.
Topics: Anti-Infective Agents; Chlamydia trachomatis; Ciprofloxacin; Clindamycin; Drug Resistance, Microbial; Erythromycin; Fleroxacin; Microbial Sensitivity Tests; Tetracyclines | 1988 |
Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Culture Media; Fleroxacin; Hydrogen-Ion Concentration; Methods; Norfloxacin | 1988 |
Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
Topics: Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Fleroxacin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus | 1988 |
Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones | 1988 |
In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms | 1988 |
In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.
Topics: Anti-Infective Agents; Chlamydia trachomatis; Ciprofloxacin; Doxycycline; Fleroxacin; Fluoroquinolones; Minocycline; Norfloxacin; Ofloxacin; Quinolones | 1988 |
Comparative activities of three new antibacterial agents with aztreonam against gram-negative bacilli.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftizoxime; Ciprofloxacin; Drug Therapy, Combination; Enterobacteriaceae; Fleroxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1987 |
In vitro characterization of Ro 23-6240.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Microbial Sensitivity Tests; Pseudomonas | 1987 |
Activity of Ro 236240, Ro 158074 and Ro 195247 against resistant gonococci.
Topics: Anti-Bacterial Agents; Cefmenoxime; Ceftizoxime; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Humans; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 1987 |
Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.
Topics: Administration, Oral; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Fleroxacin; Half-Life; Humans; Infusions, Intravenous; Metabolic Clearance Rate | 1987 |
Single dose therapy with Ro 23-6240 in patients suffering from acute, non-complicated gonococcal infection.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Gonorrhea; Humans; Male | 1987 |
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones; Sensitivity and Specificity | 1995 |
Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Ileum; Jejunum; Male; Quinolones; Rats; Rats, Sprague-Dawley | 1995 |
Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1995 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
In vitro activity of eight antibiotics against Salmonella and Shigella species.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fleroxacin; Microbial Sensitivity Tests; Ofloxacin; Pefloxacin; Salmonella; Shigella; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
The inhibitory effect of fluoroquinolones on Coxiella burnetii growth in in-vitro systems.
Topics: Animals; Anti-Infective Agents; Chick Embryo; Chlorocebus aethiops; Ciprofloxacin; Coxiella burnetii; Fleroxacin; Microbial Sensitivity Tests; Minocycline; Pefloxacin; Vero Cells | 1994 |
Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Ceftazidime; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure | 1994 |
Photodegradation of some quinolones used as antimicrobial therapeutics.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Light; Mass Spectrometry; Ofloxacin; Photochemistry; Spectrophotometry, Ultraviolet; Ultraviolet Rays | 1994 |
Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway?
Topics: Biological Transport; Carbon Radioisotopes; Cells, Cultured; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Humans; Intestinal Mucosa; Norfloxacin; Ofloxacin; Pefloxacin; Quinolizines | 1994 |
A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1993 |
In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Culture Media; Fleroxacin; Fluoroquinolones; Horses; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1993 |
Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Embryo, Mammalian; Female; Fleroxacin; Fluoroquinolones; Macaca fascicularis; Norfloxacin; Pregnancy; Pregnancy, Animal; Quinolones | 1993 |
In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1995 |
Detection of quinolone-resistant Neisseria gonorrhoeae.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Female; Fleroxacin; Fluoroquinolones; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Ofloxacin; Quinolones; Reference Standards | 1996 |
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 1996 |
The photomutagenicity of fluoroquinolones in tests for gene mutation, chromosomal aberration, gene conversion and DNA breakage (Comet assay).
Topics: Animals; Anti-Infective Agents; Carcinogens; Chromosome Aberrations; Ciprofloxacin; Cricetinae; DNA Damage; Fleroxacin; Fluoroquinolones; Gene Conversion; Lymphoma; Methoxsalen; Mice; Mitosis; Mutagenicity Tests; Mutagens; Mutation; Photosensitizing Agents; Quinolones; Saccharomyces cerevisiae; Salmonella; Tumor Cells, Cultured; Ultraviolet Rays | 1996 |
In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites.
Topics: Benzimidazoles; Binding Sites; Calcium; Ciprofloxacin; Fleroxacin; Magnesium; Molecular Structure; Plasmids; Pyrimidines; Topoisomerase II Inhibitors | 1997 |
Fluoroquinolone antibacterials enhance UVA-induced skin tumors.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fleroxacin; Fluoroquinolones; Mice; Nalidixic Acid; Neoplasms, Radiation-Induced; Ofloxacin; Quinolones; Skin Neoplasms; Ultraviolet Rays | 1997 |
Quinolone antibacterials: a new class of photochemical carcinogens.
Topics: Animals; Anti-Infective Agents; Carcinoma, Squamous Cell; Ciprofloxacin; Dermatitis, Phototoxic; Fleroxacin; Fluoroquinolones; Methoxsalen; Mice; Mice, Hairless; Nalidixic Acid; Neoplasms, Radiation-Induced; Ofloxacin; Papilloma; Quinolones; Skin Neoplasms | 1997 |
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Quinolones | 1997 |
Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Topics: Animals; Anti-Infective Agents; Bone Marrow; Cells, Cultured; Ciprofloxacin; Cobalt Radioisotopes; Colony-Forming Units Assay; Culture Media, Conditioned; Fleroxacin; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Hemoglobins; Interleukin-3; Leukocyte Count; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Norfloxacin; Ofloxacin; Quinolones; Whole-Body Irradiation | 1997 |
Endothelial cell compatibility of fluoroquinolone solutions for intravenous use.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine Triphosphate; Anti-Infective Agents; Cell Survival; Cells, Cultured; Ciprofloxacin; Endothelium, Vascular; Epoprostenol; Firefly Luciferin; Fleroxacin; Humans; Injections, Intravenous; Luciferases; Ofloxacin; Radioimmunoassay; Thromboxane A2; Umbilical Veins | 1997 |
Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds.
Topics: 1-Naphthylamine; Anti-Infective Agents; Azithromycin; Bacterial Outer Membrane Proteins; Burkholderia cepacia; Cations; Ceftazidime; Cell Membrane Permeability; Ciprofloxacin; Clarithromycin; Fleroxacin; Fluorescent Dyes; Fluoroquinolones; Gentamicins; Magnesium; Microbial Sensitivity Tests; Microscopy, Electron; Novobiocin; Oxolinic Acid; Polysaccharides, Bacterial; Tobramycin | 1997 |
The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro.
Topics: Animals; Anti-Infective Agents; Carcinoma, Transitional Cell; Cell Count; Cell Division; Cell Survival; Ciprofloxacin; Dose-Response Relationship, Drug; Fleroxacin; Humans; Mice; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics.
Topics: Age Factors; Animals; Anti-Infective Agents; Calcium; Cartilage; Ciprofloxacin; Contraindications; Female; Fleroxacin; Joint Diseases; Knee Joint; Magnesium; Magnesium Deficiency; Male; Ofloxacin; Rats; Rats, Wistar | 1997 |
Photosensitivity induced by lomefloxacin with cross-photosensitivity to ciprofloxacin and fleroxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Dermatitis, Photoallergic; Fleroxacin; Fluoroquinolones; Humans; Male; Quinolones | 1998 |
Endothelial purine content. An alternative model for testing antibiotic solutions for intravenous use.
Topics: Adenosine Triphosphate; Anti-Infective Agents; Cell Survival; Cells, Cultured; Ciprofloxacin; Drug Evaluation, Preclinical; Endothelium, Vascular; Epoprostenol; Fleroxacin; Humans; Ofloxacin; Solutions; Thromboxane A2; Umbilical Veins | 1998 |
Effects of fluoroquinolones and magnesium deficiency in murine limb bud cultures.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryonic and Fetal Development; Extremities; Fleroxacin; Fluoroquinolones; Magnesium Deficiency; Mice; Microscopy, Electron; Ofloxacin; Pefloxacin; Quinolones | 1998 |
[Fluoroquinolones as etiology of tendinopathy].
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fleroxacin; Humans; Male; Middle Aged; Risk Factors; Rupture, Spontaneous; Tendinopathy; Tendon Injuries | 1998 |
Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Fleroxacin; Fusidic Acid; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Streptomycin | 1995 |
Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy.
Topics: Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Hematologic Neoplasms; Humans; Naphthyridines; Neutropenia; Risk Factors; Streptococcal Infections; Streptococcus | 1999 |
In vitro phototoxicity of new quinolones: production of active oxygen species and photosensitized lipid peroxidation.
Topics: Anti-Infective Agents; Ciprofloxacin; Dermatitis, Phototoxic; DNA Damage; Fleroxacin; Fluoroquinolones; Humans; Lipid Peroxidation; Norfloxacin; Ofloxacin; Quinolones; Reactive Oxygen Species; Squalene; Time Factors; Ultraviolet Rays | 1999 |
Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Biological Availability; Ciprofloxacin; Fleroxacin; Humans; Male; Reference Values | 2000 |
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Cell Line; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Infusions, Intra-Arterial; Kidney; Mice; Mice, Inbred Strains; Mice, Knockout; Microdialysis; Norfloxacin; Pefloxacin; Recombinant Proteins; Rhodamine 123; Swine; Tissue Distribution; Transfection | 2000 |
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; beta-Alanine; Biphenyl Compounds; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Convulsants; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Imipenem; Injections, Intravenous; Injections, Intraventricular; Male; Mice; Mice, Inbred ICR; Norfloxacin; Oxazines; Penicillin G; Quinolones; Seizures; Thienamycins | 2002 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Mass spectrometic study of speciation in aluminium-fluoroquinolone solutions.
Topics: Aluminum; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Humans; Intestinal Absorption; Models, Chemical; Moxifloxacin; Quinolines; Solutions; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2012 |
Upconversion particle@Fe
Topics: Animals; Biosensing Techniques; Ciprofloxacin; Enoxacin; Enrofloxacin; Erbium; Fishes; Fleroxacin; Fluorescent Dyes; Fluorides; Fluoroquinolones; Levofloxacin; Magnetite Nanoparticles; Molecular Imprinting; Quinolones; Reproducibility of Results; Seafood; Ytterbium; Yttrium | 2018 |
Antibiotics and efflux: combined spectrofluorimetry and mass spectrometry to evaluate the involvement of concentration and efflux activity in antibiotic intracellular accumulation.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cytoplasm; Fleroxacin; Gram-Negative Bacteria; Mass Spectrometry; Spectrometry, Fluorescence | 2019 |
Collection and Separation of Fleroxacin and Ciprofloxacin in Ultrasound-Assisted Ionic Liquid Salting-Out Microextraction System.
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans; Ionic Liquids; Limit of Detection; Linear Models; Liquid Phase Microextraction; Rabbits; Reproducibility of Results; Rivers; Sodium Chloride; Sonication; Temperature | 2020 |
Association between fluoroquinolone exposure and children's growth and development: A multisite biomonitoring-based study in northern China.
Topics: Animals; Anti-Bacterial Agents; Biological Monitoring; Child; China; Ciprofloxacin; Enrofloxacin; Fleroxacin; Fluoroquinolones; Humans; Obesity; Ofloxacin; Overweight | 2022 |